Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 15/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382836 | 0.90 | HTR7 (0.51) | HTR7ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL4376134 | 0.90 | HTR7 (0.51) | HTR7ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL4373322 | 0.89 | HTR7 (0.50) | HTR7ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL4375847 | 0.80 | HTR7 (0.49) | HTR7ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL4373099 | 0.76 | HTR7 (0.53) | HTR7HTR2C | |
| SCHEMBL4373019 | 0.75 | HTR7 (0.49) | HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL4385405 | 0.74 | HTR7 (0.85) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL4377382 | 0.74 | HTR7 (0.56) | HTR7 | |
| SCHEMBL4375495 | 0.73 | APP (0.46) | HTR7 | |
| SCHEMBL4372829 | 0.73 | HTR7 (0.58) | HTR7ADRA1DADRA1AADRA1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | claimed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | claimed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | claimed |
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | disclosed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032199-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | HTR7 1/4885ADRA1D 153/4885ADRA1A 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.